Bausch + Lomb Stock Sinks on ‘Voluntary Recall’ of Some Implantable Eye Lenses

Published March 28, 2025

02:33 PM EDT

Bausch + Lomb (BLCO) shares tumbled in intraday trading Friday, a day after the eye-care company announced a “voluntary recall” of some of its intraocular lenses due to safety concerns.

On Thursday, Bausch + Lomb said it was recalling its enVista Aspire and enVista Envy lenses and some enVista monofocal lenses in the U.S. after the company received an increased number of reports of toxic anterior segment syndrome (TASS) caused by the lenses. The company announced the recall “out of an abundance of caution” and noted that it couldn’t immediately explain the causes for the complications.

Intraocular lenses, or IOLs, are artificial lenses implanted in the eye during cataract surgery to replace the natural lens and are aimed at improving vision.

TASS, an inflammatory reaction inside the eye, is “a potential complication in any cataract surgery” and typically appears between 12 and 48 hours after eye surgery, Bausch + Lomb said.

Shares of Bausch + Lomb are down almost 5% in intraday trading Friday and have lost about 17% of their value in the past year.

Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.